Mayne Pharma Group Limited
Mayne Pharma Group Limited
- P/E ratio
- 19.55
Your view on MYX.AX
Overview
What the company does, where it operates, and who runs it.
About Mayne Pharma Group Limited
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Aaron Gray
- Headquarters
- 1538 Main North Road, Salisbury South, SA, AU
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Aaron Gray
- Headquarters
- 1538 Main North Road, Salisbury South, SA, AU
Mayne Pharma Group Ltd. operates as a specialized pharmaceutical enterprise, dedicated to the global production and distribution of both proprietary (branded) and unbranded (generic) medicinal products. Its extensive market reach spans Australia, New Zealand, North America (the United States and Canada), Europe, and Asia.
The company's business activities are organized across four distinct divisions: Metrics Contract Services, International, Branded Products, and Portfolio Products.
Mayne Pharma offers innovative oral drug delivery technologies and provides comprehensive contract services, including pharmaceutical development, manufacturing, and analytical support to external clients.
Furthermore, the firm specializes in the distribution of pharmaceutical products tailored for key therapeutic areas such as dermatology, women's health, and infectious diseases.
Incorporated in 2005, and headquartered in Salisbury South, Australia, the company was formerly known as Halcygen Pharmaceuticals Limited before rebranding to Mayne Pharma Group Limited in November 2010.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Mayne Pharma Group Limited. Starting points for Mayne Pharma Group Limited: P/E 19.5, EPS AUD 0.30, beta 1.00 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Mayne Pharma Group Limited. Mayne Pharma Group Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Mayne Pharma Group Limited. Trailing twelve-month EPS for Mayne Pharma Group Limited stands at AUD 0.30. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterDec 2014 | Next quarterJun 2021 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | AUD 0.03 | AUD 0.02 | −AUD 0.36 | −AUD 0.22 |
| Lowest estimate | AUD 0.03 | AUD 0.01 | −AUD 0.48 | −AUD 0.22 |
| Highest estimate | AUD 0.03 | AUD 0.05 | −AUD 0.25 | −AUD 0.22 |
| Number of analysts | 2 | 10 | 2 | 2 |
| A year ago | — | — | AUD 0.211 | — |
| Growth vs a year ago | — | — | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2014 | Next quarterJun 2021 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | AUD 66.58M | AUD 546.78M | AUD 375.90M | AUD 322.73M |
| Lowest estimate | AUD 63.63M | AUD 487.22M | AUD 366.31M | AUD 305.70M |
| Highest estimate | AUD 66.91M | AUD 624.10M | AUD 380.79M | AUD 336.30M |
| Number of analysts | 2 | 9 | 3 | 3 |
| A year ago | — | — | AUD 383.68M | — |
| Growth vs a year ago | — | — | −2.0% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Mayne Pharma Group Limited. Mayne Pharma Group Limited has reported as a listed company since 2007. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| AVE.AXAvecho Biotechnology Limited | Healthcare | Biotechnology | — | ||
| CAN.AXCann Group Limited | Healthcare | Drug Manufacturers - Specialty & Generic | — | ||
| EPN.AXEpsilon Healthcare Limited | Healthcare | Drug Manufacturers - Specialty & Generic | — | ||
| EXL.AXElixinol Wellness Limited | Healthcare | Drug Manufacturers - Specialty & Generic | — | ||
| IDT.AXIDT Australia Limited | Healthcare | Drug Manufacturers - Specialty & Generic | — | ||
| LGP.AXLittle Green Pharma Ltd | Healthcare | Drug Manufacturers - Specialty & Generic | — | ||
| RGT.AXArgent BioPharma Limited | Healthcare | Drug Manufacturers - Specialty & Generic | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| COSMCosmos Health Inc. | Healthcare | NASDAQ | $14.8M | ||
| CSCI.TOCOSCIENS Biopharma Inc. | Healthcare | TSX | $8.6M | ||
| CSCIFCOSCIENS Biopharma Inc. | Healthcare | OTC | $6.0M | ||
| CSMYFCOSMOS Pharmaceutical Corporation | Healthcare | OTC | $3.8B | ||
| CTORCitius Oncology, Inc. | Healthcare | NASDAQ | $51.8M | ||
| CTTHCTT Pharmaceutical Holdings, Inc. | Healthcare | OTC | $1.9M | ||
| CUVLClinuvel Pharmaceuticals Ltd. | Healthcare | NASDAQ | $245.1M | ||
| CXBSCorix Bioscience, Inc. | Healthcare | OTC | $2,734 | ||
| CYBN.NECybin Inc. | Healthcare | NEO | — | ||
| DECNDecision Diagnostics Corp. | Healthcare | OTC | $35,450 | ||
| DOSEFDoseology Sciences Inc. | Healthcare | OTC | $1.7M | ||
| EBM.VEastwood Bio-Medical Canada Inc. | Healthcare | TSXV | $44.1M | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| VXUSVanguard Total International Stock ETF | $163.2B in assets | 0.00% | |
| VEAVanguard FTSE Developed Markets ETF | $231.6B in assets | 0.00% | |
| VSSVanguard FTSE All-World ex-US Small-Cap ETF | $11.6B in assets | 0.00% | |
| AVDVAvantis International Small Cap Value ETF | $19.2B in assets | — | |
| DFISDimensional - International Small Cap ETF | $5.8B in assets | 0.00% | |
| DFICDimensional - International Core Equity 2 ETF | $15.4B in assets | 0.00% | |
| VIU.TOVanguard FTSE Developed All Cap ex North America Index ETF | $11.4B in assets | 0.00% | |
| VSGXVanguard ESG International Stock ETF | $6.7B in assets | 0.00% | |
Largest holders first, then the funds most concentrated in MYX.AX.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Mayne Pharma Group Limited. Coverage tracks Mayne Pharma Group Limited within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Mayne Pharma Group Limited.